PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Health Canada Approves Novartis’ Fabhalta for PNH with Haemolytic Anaemia

The decision is supported by findings from the Phase III APPLY-PNH trial.

Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with paroxysmal nocturnal haemoglobinuria (PNH) and haemolytic anaemia.

The Notice of Compliance issued by Health Canada approving Fabhalta is supported by findings from the Phase III APPLY-PNH trial, which involved subjects with residual anaemia despite previous anti-C5 treatment who switched to the therapy.

Further backing comes from the Phase III APPOINT-PNH trial, which included complement inhibitor-naïve subjects.

Clinical trials have demonstrated that the therapy provides superior haemoglobin improvement without the need for red blood cell transfusions.

The therapy is the only Factor B inhibitor approved in the country, offering comprehensive control of red blood cell destruction, both within and outside blood vessels.

Its clinical safety and cost-effectiveness are currently under review by Canada’s Drug Agency and Institut National d’Excellence en Santé et Services Sociaux.

Novartis Canada country president Mark Vineis stated: “We are proud that Fabhalta has received approval to bring a new oral medicine to Canadians living with PNH, a chronic and life-altering blood disease.

“This new treatment option provides renewed hope for patients, their loved ones and the healthcare providers who care for them.”

The therapy is accessible only via a controlled distribution programme, which requires prescribers to enrol subjects and confirm their vaccination against encapsulated bacteria.

PNH is characterised by the inappropriate or excessive activation of the complement system.

Novartis Pharmaceuticals Canada has a team of 600 focused on addressing the changing needs of patients and the healthcare system. The company invests more than $30m annually in research and development within the country.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026